$AEHR

SLAYEN HOWARD T sold $2.2M of AEHR

SLAYEN HOWARD T (Director) sold 20,000 shares of AEHR TEST SYSTEMS (AEHR) at $108.30 ($2.17M total) on 2026-08-04.

Original reporting
SEC EDGAR · SLAYEN HOWARD T
Published Aug 5, 2026, 1:16 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 5, 2026, 2:07 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$AEHR
Neutral
medium confidence
Mentioned
$AEHR
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AEHRNeutralLow
01

Why it matters

A director’s open-market sale of $2.17M is new information for traders monitoring insider behavior, but it does not include any guidance, deal, regulatory action, or operational update.

02

Market read

Traders may briefly reassess sentiment toward AEHR based on the disclosed insider sale size and timing, but the filing lacks fundamental catalysts.

03

What to watch

Insider sales can be misread without context such as prior holdings, compensation structure, and whether other insiders are selling or buying around the same period.

Relevance 6/10Novelty 3/10Timing: filed 2026-08-04 after-hours; sale dated 2026-08-04

Background

The article is a SEC Form 4 insider transaction disclosure for AEHR Test Systems.

Company-level read

Ticker impact

$AEHRNeutralMedium confidence
Context

AEHR director Slayen Howard T sold 20,000 shares in an open-market transaction at $108.2961 on 2026-08-04, totaling $2.17M.

Expected impact

Likely limited, short-lived sentiment impact; watch for follow-on selling or unusual volume around the filing date.

Evidence & confidence

The filing is a Form 4 insider transaction with a specific sale price and size, but it provides no new company-specific operational or financial information.

Market effects

No direct sector read-through; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

The sale may be routine liquidity or tax-related, especially since the filing notes no 10b5-1 plan, so it could reflect personal timing rather than a view on AEHR.

Key entities

  • AEHR Test Systems

    Company whose director insider sale is disclosed via Form 4.

  • Slayen Howard T

    Director who sold 20,000 shares at $108.2961 on 2026-08-04.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AEHRMed

AEHR Stock Rides AI Order Wave Amid Volatility

Aehr Test Systems (AEHR) stock rose 13.28% following strong earnings and a positive outlook for semiconductor test demand. The company reported $50M in revenue, $18.8M in quarterly revenue, and a net income of $1.39M. Jefferies initiated coverage with a Buy rating and $175 price target, citing AEHR's role in AI production. The stock has shown volatility, with a recent drop of 9.5-10.5% in a single session. Insiders have sold shares but maintain significant holdings. AEHR is actively presenting a

$AEHRHigh

AEHR Stock Rallies As AI Orders And Wall Street Support Build

Aehr Test Systems (AEHR) stock rose 11.71% due to strong AI-related demand. The company reported $18.8M in revenue with a 35.3% gross margin. Jefferies initiated coverage with a Buy rating and $175 price target, citing AEHR's role in AI chip production. The company has a strong balance sheet and a $22M follow-on order from a major customer.

$AEHRHigh

AEHR Stock Rallies As AI Test Orders And Wall Street Support Grow

Aehr Test Systems (NASDAQ: AEHR) stock rose 11.73% on growing AI test demand. The company secured a $22M follow-on order for AI chip testing equipment. Jefferies initiated coverage with a Buy rating and $175 price target, citing AEHR's unique position in AI production testing. The stock has high volatility, with a strong balance sheet but negative EBIT margins.